#FDA approval

September 4, 2019, the U.S. FDA released their recent approval of new dosage forms of Sovaldi and Harvoni for children 3 to 12 years of age.

A placebo-controlled study of obeticholic acid showed it improved liver fibrosis with no worsening of non-alcoholic steatohepatitis.

Stella Armstrong’s journey to a healthier life wasn’t easy.

Between August 2018 and January 2019, the FDA doubled the number of liver cancer treatments.

The U.S. FDA approved hepatitis C treatment Mavyret for children from ages 12 to 17 with all genotypes.

With the approval of Cyramza, there are now five targeted therapies for hepatocellular carcinoma.

The spray requires no medical training.

A placebo-controlled study of obeticholic acid showed it improved liver fibrosis with no worsening of non-alcoholic steatohepatitis.

Cabometyx is the third liver cancer drug approved in the past six months.

Four out of 10 FDA workers are sidelined.

A second immunotherapy option is now available for hepatocellular carcinoma.

Gilead Sciences has released multiple combo tablets that contain the updated tenofovir, which is linked to improved bone and kidney makers.

Lenvima works as well as standard therapy for metastatic or unresectable cancer.

A speedy overview of the major scientific findings presented at the International AIDS Conference in Amsterdam (AIDS 2018)

Lucemyra is approved to treat the symptoms of opioid withdrawal for 14 days.

The Phase IIa trial will test the drug CC-31244 in combination with approved hepatitis C medications.